Short-term effects of rituximab on flow-mediated dilatation may be mediated by intravenous glucocorticoids: comment on the article by Gonzalez-Juanatey et al

Arthritis Rheum. 2009 Jun 15;61(6):854-5; author reply 855-6. doi: 10.1002/art.24582.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / physiopathology
  • Blood Proteins / drug effects
  • Drug Therapy, Combination
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / pharmacology*
  • Humans
  • Infusions, Intravenous
  • Lipids / blood
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / pharmacology*
  • Regional Blood Flow / drug effects
  • Regional Blood Flow / physiology
  • Rituximab
  • Vasodilation / drug effects
  • Vasodilation / physiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Blood Proteins
  • Glucocorticoids
  • Lipids
  • Rituximab
  • Methylprednisolone